Tabis Plus 5

Indications of Tabis Plus 5 Tablet

Bisoprolol plus Hydrochlorothiazide is indicated in the treatment of Hypertension.

Pharmacology of Tabis Plus 5 Tablet

Bisoprolol Fumarate and Hydrochlorothiazide have been utilized exclusively and in combination for the treatment of hypertension. The antihypertensive impacts of these operators are added substance; Hydrochlorothiazide 6.25 mg altogether increments the antihypertensive impact of Bisoprolol Fumarate. The frequency of hypokalemia with the Bisoprolol Fumarate and Hydrochlorothiazide 6.25 mg combination is essentially lower than with Hydrochlorothiazide 25 mg. Bisoprolol Fumarate may be a β1-selective (cardioselective) adrenoceptor blocking specialist without critical film stabilizing or inborn sympathomimetic activities in its restorative dosage extend. Hydrochlorothiazide may be a benzothiadiazine diuretic. Thiazides influence renal tubular instruments of electrolyte reabsorption and increment excretion of sodium and chloride in roughly proportionate sums

Dosage & Administration of Tabis Plus 5 Tablet

Bisoprolol is an effective treatment of hypertension in once-daily doses of 2.5 mg to 40 mg, while hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg. In clinical trials of bisoprolol/hydrochlorothiazide combination therapy using bisoprolol doses of 2.5 mg to 20 mg and hydrochlorothiazide doses of 6.25 mg to 25 mg.

Interaction of Tabis Plus 5 Tablet

Bisoprolol should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs should be closely monitored, because the added beta-adrenergic blocking action of Bisoprolol may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that Bisoprolol be discontinued for several days before the withdrawal of clonidine. Bisoprolol should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists or antiarrhythmic agents are used concurrently. Concomitant use with digitalis glycosides can increase the risk of bradycardia. Concurrent use of rifampin increases the metabolic clearance of Bisoprolol, resulting in a shortened elimination half-life of Bisoprolol. However, initial dose modification is generally not necessary

Contraindications

Bisoprolol fumarate and hydrochlorothiazide is contraindicated in patients in cardiogenic shock, overt cardiac failure, second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.

Side Effects of Tabis Plus 5 Tablet

Generally well tolerated. Most side effects have been mild and transient. Normally fatigue, dizziness, headache, bradycardia, arrhythmia, peripheral ischemia, chest pain, palpitations, rhythm disturbances, cold extremities, claudication, orthostatic hypotension, diarrhoea, constipation, nausea, dyspepsia, rhinitis, pharyngitis etc. may occur

Pregnancy & Lactation

Nursing Mothers: Thiazides are excreted in human breast milk. Small amounts of bisoprolol fumarate (<2% of the dose) have been detected in the milk of lactating rats. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Use in Pregnancy: Pregnancy Category C.

Precautions & Warnings

Dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances are potential syndrome of fluid and electrolyte imbalance. Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than salt administration. Hyperuricemia or acute gout may be precipitated in certain patients receiving thiazide diuretics. Bisoprolol nfumarate, alone or in combination with hydrochlorothiazide, has been associated with increases in uric acid.

Therapeutic Class

Combined antihypertensive preparations

Storage Conditions

Store in a cool and dry place, protected from light.

Pharmaceutical Name of Tabis Plus 5 Tablet

Navana Pharmaceuticals Ltd

Generic of Tabis Plus 5 Tablet

Bisoprolol Fumarate + Hydrochlorothiazide